Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
2 additional source qualifications - review before use
The source assigns different starting frequencies to ranges that share 50 as a boundary, and prints clearance normalized to 1.73 m2.
Before applying: Confirm the exact product label and boundary interpretation before prescribing. The tool does not resolve this by rounding, averaging or converting an indexed measure silently.
Also check: The printed renal bands overlap at exactly 50; Exactly 50 occurs in two printed renal bands
Rxlist source
GlobalRPh RX List - ZAVESCA
Product / population
Adult ZAVESCA for mild/moderate type 1 Gaucher disease when enzyme replacement is not an option.
Renal measure
BSA-adjusted creatinine clearance, mL/min/1.73 m2; overlapping printed endpoint at 50.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
For adult type 1 Gaucher disease, the source starts 100 mg twice daily in its adjusted-CrCl 50-70 band and 100 mg once daily in its 30-50 band; the printed unit is mL/min/1.73 m2. It does not recommend use below 30. Exactly 50 appears in both printed bands and needs clarification before selecting a starting schedule. These are product-specific starting regimens, not interchangeable instructions for another miglustat indication.
Source revision: November 2017 | Retrieved: 2026-09-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Important v3.7 source / product limitation: Boundary ambiguity: exactly 50 appears in two source starting-dose bands. Do not silently choose a band or convert the printed normalized clearance.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
source ambiguity
The printed renal bands overlap at exactly 50
The selected source uses an indexed creatinine-clearance unit and overlapping renal ranges.
How to use this: Do not silently convert units or choose an unsupported boundary. Confirm the current product label and clarify the exact threshold.
Source difference identified; final patient-specific adjudication required.
ambiguous threshold
Exactly 50 occurs in two printed renal bands
The source assigns different starting frequencies to ranges that share 50 as a boundary, and prints clearance normalized to 1.73 m2.
How to use this: Confirm the exact product label and boundary interpretation before prescribing. The tool does not resolve this by rounding, averaging or converting an indexed measure silently.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - Zavesca
Adult type 1 Gaucher disease; not a miglustat combination regimen for a different disease.
Method: Adjusted CrCl, mL/min/1.73 m2, as printed.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Adult type 1 Gaucher disease; not a miglustat combination regimen for a different disease.
Renal method: Adjusted CrCl, mL/min/1.73 m2, as printed. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Start 100 mg twice daily for adjusted CrCl 50 to 70 mL/min/1.73 m2. Start 100 mg once daily for adjusted CrCl 30 to 50. Use below 30 is not recommended. The source bands overlap at 50; this local extract preserves that ambiguity rather than choosing an unsupported boundary. Hemodialysis disposition has not been investigated.
RDM33-rxlist-miglustat-zavesca-C1 · Source locator: Dosage: patients with renal insufficiency; use in specific populations: renal impairment.
Source-specific limits
Source-boundary ambiguity at exactly 50; confirm the applicable current product label and clinician interpretation.
GlobalRPh-hosted RX List · Adult ZAVESCA for mild/moderate type 1 Gaucher disease when enzyme replacement is not an option.
Renal method: BSA-adjusted creatinine clearance, mL/min/1.73 m2; overlapping printed endpoint at 50. Source date: November 2017 Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For adult type 1 Gaucher disease, the source starts 100 mg twice daily in its adjusted-CrCl 50-70 band and 100 mg once daily in its 30-50 band; the printed unit is mL/min/1.73 m2. It does not recommend use below 30. Exactly 50 appears in both printed bands and needs clarification before selecting a starting schedule. These are product-specific starting regimens, not interchangeable instructions for another miglustat indication.
RDM37-rxlist-miglustat-zavesca-1046500eaf-C1 · Source locator: Dosage: Patients With Renal Insufficiency.
Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.